Herba epimedii water extract elevates estrogen level and improves lipid metabolism in postmenopausal women

Phytotherapy Research

Volumn 22, Issue 9, 2008, Pages 1224-1228

  Yan, Fang Fang ^a   Liu, Yan ^a   Liu, Yun Fang ^a   Zhao, Yu Xia ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Herba epimedii; Lipid metabolism; Sex hormone

Indexed keywords

CHOLESTEROL; ESTRADIOL; HERBA EPIMEDII EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLANT EXTRACT; PROGESTERONE; SEX HORMONE; TESTOSTERONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; WATER;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; ESTRADIOL BLOOD LEVEL; FEMALE; HERBA EPIMEDII; HUMAN; KIDNEY DISEASE; LIPID METABOLISM; LIVER DISEASE; MAJOR CLINICAL STUDY; MEDICINAL PLANT; POSTMENOPAUSE; PROGESTERONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL;

ADULT; AGED; DOUBLE-BLIND METHOD; ESTROGENS; FEMALE; HUMANS; LIPID METABOLISM; MIDDLE AGED; PLACEBOS; PLANT EXTRACTS; POSTMENOPAUSE; PROGESTERONE; TESTOSTERONE; WATER;

EID: 52649108675     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2451     Document Type: Article

References (32)

1. Adlercreutz H, Mazur W. 1997. Phyto-oestrogens and Western diseases. Ann Med 29: 95-120.
2. Anthony M, Williams JK, Dunn BK. 2001. What would be the properties of an ideal SERM? Ann NY Acad Sci 949: 261-278.
3. Austin MA, Hokanson JE, Edwards KL 1998. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81: 7B-12B.
4. Bairey Merz CN, Johnson BD, Braunstein GD et al. 2006. Phytoestrogens and lipoproteins in women. J Clin Endocrinol Metab 91: 2209-2213.
5. Balk JL, Whiteside DA, Naus G, DeFerrari E, Roberts JM. 2002. A pilot study of the effects of phytoestrogen supplementation on postmenopausal endometrium. J Soc Gynecol Investig 9: 238-242.
6. Beral V, Bull D, Reeves G, Million Women Study Collaborators. 2005. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365: 1543-1551.
7. Chen KM, Ge BF, Ma HP, Liu XY, Bai MH, Wang Y. 2005. Icariin, a flavonoid from the herb Epimedium enhances the osteogenic differentiation of rat primary bone marrow stromal cells. Pharmazie 60: 939-942.
8. Christodoulakos GE, Lambrinoudaki IV, Panoulis CP, Papadias CA, Kouskouni EE, Creatsas GC. 2004. Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein (a) in Greek postmenopausal women. Gynecol Endocrinol 18: 244-257.
9. Collins P, Flather M, Lees B, Mister R, Proudler AJ, Stevenson JC, WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. 2006. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP pilot Study. Eur Heart J 27: 2046-2053.
10. Conzen SD. 2003. Current status of selective estrogen receptor of modulators (SERMs) [J]. Cancer J 9: 4-14.
11. Crisafulli A, Altavilla D, Marini H et al. 2005. Effects of the phytoestrogen genistein on cardiovascular risk factors in postmenopausal women. Menopause 12: 186-192.
12. Dai Q, Franke AA, Yu H et al. 2003. Urinary phytoestrogen excretion and breast cancer risk: evaluating potential effect modifiers endogenous estrogens and anthropometrics. Cancer Epidemiol Biomarkers Prev 12: 497-502.
13. Friedewald WT, Levy Rl, Fredrickson DS. 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502.
14. Gregoriou O, Christodoulakos G, Siristatidis C, Conidaris S, Kouskouni E, Creatsas G. 2002. Continuous combined replacement therapy in postmenopausal women: effect on plasma lipoproteins, bone mass and the endometrium. Hormones (Athens) 1: 239-244.
15. Lacey JV Jr, Brinton LA, Lubin JH, Sherman ME, Schatzkin A, Schairer C. 2005. Endometrial carcinoma risk among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev 14: 1724-1731.
16. Le Bail JC, Champavier Y, Chulia AJ, Habrioux G. 2000. Effects of phytoestrogens on aromatase, 3 beta and 17 beta-hydroxysteroid dehydrogenase activities and human breast cancer cells. Life Sci 66: 1281-1291.
17. Lobo RA, Bush T, Carr BR, Pickar JH. 2001. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 76: 13-24.
18. Mosca L. 2000. Hormone replacement therapy in the prevention and treatment of atherosclerosis. Curr Atheroscler Rep 2: 297-302.
19. Park D, Huang T, Frishman WH. 2005. Phytoestrogens as cardioprotective agents. Cardiol Rev 13: 13-17.
20. Rossouw JE, Anderson GL, Prentice RL et al. 2002. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333.
21. Scheiber MD, Lin JH, Subbiah MT, Rebar RW, Setchell KD. 2001. Dietary inclusion whole soy foods results in significant reductions in clinical risk factors for osteoporosis and cardiovascular disease in normal postmenopausal women. Menopause 8: 384-392.
22. Simon T. 2006. Why is cardiovascular health important in menopausal women? Climacteric 9: S13-S18.
23. Stamler J, Wentworth D, Neaton JD. 1986. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256: 2823-2828.
24. Strom BL, Schinnar R, Weber AL et al. 2006. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. Am J Epidemiol 164: 775-786.
25. Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA. 2006. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med 166: 1483-1489.
26. Tham DM, Gardner CD, Haskell WL. 1998. Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanic evidence. J Clin Endocrinol Metab 83: 2233-2235.
27. Thunell L, Andersson B, Glassell M, Mattsson LA. 2006. The effect of continuous combined HRT on glucose homeostasis and plasma lipids. A placebo-controlled study in postmenopausal women with type 2 diabetes. Maturitas 53: 430-438.
28. Usui T. 2006. Pharmaceutical prospects of phytoestrogens. Endocr J 53: 7-20.
29. Wang ZQ, Lou YJ. 2004. Proliferation-stimulating effects of icariin and desmethylicaritin in MCF-7 cells. Eur J Pharmacol 504: 147-153.
30. Yap SP, Shen P, Butler MS, Gong Y, Loy CJ, Yong EL. 2005. New estrogenic prenylflavone from Epimedium brevicomum inhibits the growth of breast cancer cells. Planta Med 71: 114-119.
31. Ye HY, Lou YJ. 2005. Estrogenic effects of two derivatives of icariin on human breast cancer MCF-7 cells. Phytomedicine 12: 735-741.
32. Zhang G, Qin L, Hung WY et al. 2006. Flavonoids derived from herbal Epimedium Brevicomum Maxim prevent OVX-induced osteoporosis in rats independent of its enhancement in intestinal calcium absorption. Bone 38: 818-825.